Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
1979-7-16
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
0022-3549
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
68
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
I
|
| pubmed:dateRevised |
2008-11-21
|
| pubmed:meshHeading |
pubmed-meshheading:438956-Drug Prescriptions,
pubmed-meshheading:438956-Jurisprudence,
pubmed-meshheading:438956-Societies, Pharmaceutical,
pubmed-meshheading:438956-Therapeutic Equivalency,
pubmed-meshheading:438956-United States,
pubmed-meshheading:438956-United States Food and Drug Administration
|
| pubmed:year |
1979
|
| pubmed:articleTitle |
APhA perspective on "Lannett".
|
| pubmed:publicationType |
Editorial
|